Medpace Holdings, Inc. (MEDP)
USD 290.54
(2.93%)
USD 290.54
(2.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 363.15 Million USD | 21.27% |
| 2022 | 301.03 Million USD | 37.0% |
| 2021 | 219.73 Million USD | 17.78% |
| 2020 | 186.57 Million USD | 24.01% |
| 2019 | 150.45 Million USD | 6.77% |
| 2018 | 140.9 Million USD | 26.97% |
| 2017 | 110.97 Million USD | 0.72% |
| 2016 | 110.6 Million USD | 10.66% |
| 2015 | 102.59 Million USD | 5.85% |
| 2014 | 94.06 Million USD | 2.49% |
| 2013 | 89.38 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 119.79 Million USD | 12.38% |
| 2024 Q2 | 112.38 Million USD | 1.19% |
| 2024 Q1 | 111.06 Million USD | 17.78% |
| 2023 Q3 | 90.18 Million USD | 7.84% |
| 2023 Q2 | 83.63 Million USD | -9.26% |
| 2023 Q1 | 92.16 Million USD | 11.94% |
| 2023 FY | - USD | 21.27% |
| 2023 Q4 | 96.49 Million USD | 6.99% |
| 2022 Q3 | 89.26 Million USD | 31.09% |
| 2022 Q1 | 69.31 Million USD | 14.91% |
| 2022 FY | - USD | 37.0% |
| 2022 Q4 | 82.33 Million USD | -7.77% |
| 2022 Q2 | 68.09 Million USD | -1.76% |
| 2021 Q1 | 52.68 Million USD | -12.87% |
| 2021 FY | - USD | 17.78% |
| 2021 Q2 | 47.67 Million USD | -9.51% |
| 2021 Q4 | 60.32 Million USD | 2.16% |
| 2021 Q3 | 59.04 Million USD | 23.85% |
| 2020 Q3 | 51.36 Million USD | 47.67% |
| 2020 FY | - USD | 24.01% |
| 2020 Q4 | 60.47 Million USD | 17.73% |
| 2020 Q2 | 34.78 Million USD | -12.94% |
| 2020 Q1 | 39.95 Million USD | -3.58% |
| 2019 Q1 | 33.44 Million USD | -17.75% |
| 2019 FY | - USD | 6.77% |
| 2019 Q4 | 41.43 Million USD | 19.16% |
| 2019 Q3 | 34.77 Million USD | -13.53% |
| 2019 Q2 | 40.21 Million USD | 20.24% |
| 2018 Q3 | 37.13 Million USD | 11.05% |
| 2018 FY | - USD | 26.97% |
| 2018 Q4 | 40.66 Million USD | 9.51% |
| 2018 Q2 | 33.43 Million USD | 12.7% |
| 2018 Q1 | 29.67 Million USD | 8.59% |
| 2017 Q4 | 27.32 Million USD | -5.08% |
| 2017 Q3 | 28.78 Million USD | 3.86% |
| 2017 Q2 | 27.71 Million USD | 2.09% |
| 2017 Q1 | 27.15 Million USD | -4.45% |
| 2017 FY | - USD | 0.72% |
| 2016 Q3 | 26.82 Million USD | -6.12% |
| 2016 Q4 | 28.41 Million USD | 5.94% |
| 2016 FY | - USD | 10.66% |
| 2016 Q2 | 28.56 Million USD | 8.32% |
| 2016 Q1 | 26.37 Million USD | 92.67% |
| 2015 Q4 | 13.68 Million USD | -44.42% |
| 2015 Q3 | 24.63 Million USD | -6.86% |
| 2015 Q2 | 26.44 Million USD | 9.33% |
| 2015 Q1 | 24.18 Million USD | 0.0% |
| 2015 FY | - USD | 5.85% |
| 2014 FY | - USD | 2.49% |
| 2014 Q1 | 22.61 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biodesix, Inc. | -37.1 Million USD | 1078.77% |
| T2 Biosystems, Inc. | -43.87 Million USD | 927.699% |
| Aspira Women's Health Inc. | -16.49 Million USD | 2302.128% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 4859.975% |
| Castle Biosciences, Inc. | -45.02 Million USD | 906.576% |
| Exact Sciences Corporation | 41.87 Million USD | -767.21% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 70.176% |
| Illumina, Inc. | -608 Million USD | 159.729% |
| Standard BioTools Inc. | -54.45 Million USD | 766.862% |
| 23andMe Holding Co. | -291.87 Million USD | 224.421% |
| NeoGenomics, Inc. | -17.6 Million USD | 2162.549% |
| Neogen Corporation | 182.59 Million USD | -98.882% |
| Inotiv, Inc. | -26.5 Million USD | 1470.078% |
| Psychemedics Corporation | -251 Thousand USD | 144782.47% |
| RadNet, Inc. | 292.78 Million USD | -24.034% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 21626.556% |
| Prenetics Global Limited | -47.89 Million USD | 858.21% |
| iSpecimen Inc. | -9.1 Million USD | 4089.062% |
| OpGen, Inc. | -29.51 Million USD | 1330.568% |
| Neuronetics, Inc. | -22.75 Million USD | 1695.646% |
| Precipio, Inc. | -4.31 Million USD | 8510.213% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 4221.724% |
| Exagen Inc. | -19.15 Million USD | 1996.063% |
| Bionano Genomics, Inc. | -213.6 Million USD | 270.012% |
| CareDx, Inc | -89.65 Million USD | 505.047% |
| Check-Cap Ltd. | -17.64 Million USD | 2157.641% |
| Twist Bioscience Corporation | -176.7 Million USD | 305.514% |
| Guardant Health, Inc. | -433.3 Million USD | 183.81% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 14712.856% |
| Natera, Inc. | -383.27 Million USD | 194.75% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 880.102% |
| Sera Prognostics, Inc. | -35.28 Million USD | 1129.141% |
| OPKO Health, Inc. | -65.51 Million USD | 654.297% |
| Personalis, Inc. | -96.8 Million USD | 475.131% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 408.896% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 3886.377% |
| Myriad Genetics, Inc. | -67.8 Million USD | 635.624% |
| ICON Public Limited Company | 1.63 Billion USD | 77.743% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 21626.556% |
| MDxHealth SA | -30.46 Million USD | 1291.916% |
| Prenetics Global Limited | -47.89 Million USD | 858.21% |
| DarioHealth Corp. | -53.49 Million USD | 778.867% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 3811.398% |
| Mainz Biomed B.V. | -25.01 Million USD | 1551.961% |
| Trinity Biotech plc | -24.09 Million USD | 1606.984% |
| Sotera Health Company | 514.14 Million USD | 29.367% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 4859.975% |